- Company
- Prevnar 20 added to the National Immunization Program
- by Whang, byung-woo Mar 21, 2025 05:59am
- Pfizer is signaling full-fledged competition with the addition of its new pneumococcal vaccine, Prevnar 20, to the National Immunization Program (NIP) for children. According to industry sources on the 21st, the Korea Disease Control and Prevention Agency recently reviewed the introduction of PCV20 NIP for children during the 1st Korea Exp
- Policy
- Enhertu’s reimb may be extended to gastric cancer
- by Lee, Tak-Sun Mar 21, 2025 05:59am
- The number of patients who can use the new antibody-drug conjugate (ADC) anticancer drug ‘Enhertu Inj (trastuzumab deruxtecan, Daiichi Sankyo Korea), which has been reimbursed since April last year, is expected to be expanded to cover eligible gastric cancer patients. This is an expansion in the scope of existing patients eligible for reimb
- Company
- "Leclaza combo improves survival than Tagrisso monotherapy"
- by Son, Hyung Min Mar 21, 2025 05:58am
- It has been reported that the Leclaza plus Rybrevant combination therapy demonstrated improved overall survival (OS), in addition to progression-free survival (PFS), than Tagrisso. According to industry sources on March 20, the European Society for Medical Oncology made abstracts available for the 'European Lung Cancer Congress 2025(ELC
- Opinion
- [Reporter’s View] New Drug Trends and Choline Alfoscerate
- by Lee, Tak-Sun Mar 21, 2025 05:57am
- The Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee, which holds meetings every month, is the biggest hurdle to reimbursement in Korea and helps identify the latest new drug trends. For several years now, the keywords that have led the trend were “anticancer drugs,” “rare drugs,” “biological drug
- Company
- Hanmi and Samsung Bioepis join forces to sell Prolia similar
- by Cha, Jihyun Mar 20, 2025 06:01am
- Hanmi Pharmaceutical and Samsung Bioepis announced on the 19th that they had signed a joint sales agreement on the 18th for the domestic launch of the osteoporosis treatment Prolia biosimilar (Project name: SB16, ingredient name: denosumab) in Korea. Under the agreement, Samsung Bioepis is responsible for the production and supply of the
- Company
- Will COVID-19 vaccines be added to the NIP this year?
- by Whang, byung-woo Mar 20, 2025 06:00am
- As the government began the process of reviewing the inclusion of COVID-19 vaccines in the National Immunization Program (NIP) list, attention has been drawn to whether COVID-19 would be included in the NIP list within this year. According to industry sources on March 20, the Korea Disease Control and Prevention Agency (KDCA) and major pha
- Company
- Pfizer’s Elrexfio fails to pass CDDC's reimb review in KOR
- by Eo, Yun-Ho Mar 20, 2025 06:00am
- New treatment options in the field of multiple myeloma are having difficulty receiving reimbursement listing in Korea. Following the rejection of Janssen Korea’s ‘Tecvayli (teclistamab)' in November last year, Pfizer Korea's ‘Elrexfio (elranatamab)' also failed to pass the Health Insurance Review and Assessment Service's Cancer Disease
- Policy
- Public-private meetings on improving drug pricing system
- by Lee, Tak-Sun Mar 20, 2025 06:00am
- Attention has been gathered to recent public-private meetings regarding improving drug pricing system. This month, a public-private discussion session hosted by the Ministry of Health and Welfare (MOHW) and a meeting to discuss the negotiation system for expanded use of scope were held. On March 26, a regular meeting session was attende
- Company
- Will the monthly ₩20M Welireg be reimbursed this time?
- by Moon, sung-ho Mar 20, 2025 05:59am
- MSD Korea is re-applying for reimbursement of the rare anticancer drug ‘Welireg,’ following the re-application for reimbursement of its Keytruda Results of the first hurdle, whether the Cancer Disease Review Committee sets a reimbursement standard, are expected to determine the fate of the drug’s quick reimbursment. According to in
- Company
- GC Cell sells its Japanese bio stock to associated companies
- by Cha, Jihyun Mar 19, 2025 06:02am
- GC Group's subsidiary, GC Cell, has transferred some shares of its Japanese cell therapy company, which it acquired seven years ago, to a holding company that specializes in gene analysis within the group. The company decided that entrusting a business to a local subsidiary with business experience in the Japanese market would be more efficie
